[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"complement-3-glomerulopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:complement-3-glomerulopathy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100054117","a-study-of-complement-3-glomerulopathy-c3g-patients-treated-with-iptacopan-through-an-early-access-program-in-spain-100054117",false,"NCT07598448","A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain","Clinical Experience With Iptacopan in Adult Patients With Complement 3 Glomerulopathy (C3G): A Multicenter, Observational, Retrospective Study of Patients Treated Through an Early Access Program in Spain","ROUTE-C3G","Inclusion criteria:\n\n1. Adult patients (≥18 years).\n2. Biopsy-confirmed C3G.\n3. Patients who have received at least one dose of iptacopan through an EAP from October 2020 to June 2025.\n\nExclusion criteria:\n\n1\\. Patients treated with iptacopan through an EAP for indications other than C3G.","ALL","18 Years","100 Years",{"count":21,"type":22},35,"ESTIMATED","OBSERVATIONAL","This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.",[26],"Complement 3 Glomerulopathy",[26,28,29,30,31,32],"C3G","Iptacopan","Factor B inhibition","Alternative Complement Pathway","Early Access Program","NOT_YET_RECRUITING","2026-07-09",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":22},"2026-08-23",{"date":41,"type":22},"2026-12-15",{"name":43,"class":44},"Novartis Pharmaceuticals","INDUSTRY",{"id":46,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":47,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":48,"keywords":49,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":54,"leadSponsor":55,"locationsCount":4},"100638991",{"count":21,"type":22},[26],[26,28,29,30,31,32],"2026-06-29",{"date":52,"type":37},"2026-06-30",{"date":39,"type":22},{"date":41,"type":22},{"name":43,"class":44}]